cannabidiol solution (ST-101) / Stero Biotechs - LARVOL DELTA

Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients (clinicaltrials.gov) - P2 | N=15 | Completed | Sponsor: Stero Biotechs Ltd. | Unknown status ➔ Completed | Phase classification: P2a ➔ P2

Phase classification • Trial completion • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients (clinicaltrials.gov) - P2 | N=15 | Completed | Sponsor: Stero Biotechs Ltd. | Unknown status ➔ Completed | Phase classification: P2a ➔ P2 | N=28 ➔ 15

Enrollment change • Phase classification • Trial completion • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

New funds allocated to fund trial for Parkinson disease (TheCannabisRadar) - “The research will aim at finding out how CBD can be effective and safe to treat symptoms like hallucinations and delusions….The total investment of the trial is 1.2 m pounds and the charity is partnering with King’s College in London for the same….The study will start next year and it will be a discovery if the study finds that it helps to reduce the symptoms of the disease….This project has a time bracket of 3.5 years and is led by Parkinson’s UK in association with virtual Biotech.”

Financing

Newly added product (PRNewswire) - P2, Crohn's Disease

Pipeline update

Stero Biotechs to commence phase 2a clinical trial of cannabidiol-based formulation for patients with Crohn's disease (PRNewswire) - "Stero Biotechs...received its second Helsinki approval to move forward with a second Phase 2a clinical trial. The trial will be a randomized, double-blind, placebo-controlled, multicenter study of ST-SDCD-01, a CBD based solution in an effort to lower the steroid dosage in patients with Steroid Dependent Crohn's Disease (SDCD)."

New P2a trial